Enzictra Tablet is a pharmaceutical formulation combining Bromelain (90 mg), Trypsin (48 mg), and Rutoside (100 mg), designed to provide anti-inflammatory, proteolytic, and vascular protective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, facilitates the breakdown of proteins and exhibits anti-inflammatory and anti-edematous properties, making it effective in reducing swelling and promoting tissue repair. Trypsin, another proteolytic enzyme, aids in the degradation of fibrin and other necrotic tissue components, thereby enhancing wound healing and resolving inflammation. Rutoside, a bioflavonoid, contributes to capillary stabilization and strengthens vascular walls, reducing capillary permeability and fragility, which helps in managing conditions associated with microcirculatory disturbances. The synergistic action of these components makes Enzictra Tablet suitable for adjunctive therapy in acute and chronic inflammatory conditions, postoperative swelling, sports injuries, and vascular disorders such as chronic venous insufficiency and hemorrhoids. Administration should follow medical advice, considering contraindications such as hypersensitivity to any component and bleeding disorders. Enzictra Tablet should be used with caution in patients on anticoagulant therapy. Overall, this combination offers a multifaceted approach to inflammation management and vascular health support.